Dimerix Limited Reports Significant Revenue Growth Despite Losses
I'm PortAI, I can summarize articles.
Dimerix Limited (AU:DXB) reported a 914% increase in revenue to $5.9 million for the year ending June 30, 2025, despite a loss of $13.25 million, which is a 22% improvement from the previous year. The company did not declare dividends and continues to invest in its product development pipeline in the biotechnology sector. Analysts rate the stock as a Buy with a price target of A$1.58. Dimerix focuses on developing therapies for kidney disease and other chronic conditions.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments